• Recently, the Trump administration announced plans to propose a two-year extension of Affordable Care Act (ACA) subsidies, with expanded income eligibility and new minimum premium requirements.
• This policy development is particularly significant for Centene, as ongoing ACA subsidies form a foundation for growth in its commercial marketplace segment and underpin the company's revenue and membership guidance for 2025.
• We will now assess how extended ACA subsidies could affect Centene’s investment narrative, especially regarding commercial marketplace growth potential.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Centene Investment Narrative Recap

To be a shareholder in Centene, you need confidence in the stability and support of government-sponsored health programs, especially the Affordable Care Act (ACA), as a key driver of commercial marketplace growth. The Trump administration’s proposal to extend ACA subsidies directly addresses Centene’s biggest short-term catalyst, continued robust membership and revenue tied to ACA exchanges, while also reducing near-term policy risk that previously threatened individual marketplace earnings.

The company’s recent Q3 2025 earnings announcement is particularly relevant: Centene reported significant year-over-year revenue growth alongside a raised 2025 guidance, crediting strong ACA marketplace performance. This momentum in the commercial segment is closely linked to policy certainty around ACA subsidies, emphasizing the importance of legislative developments for future results.

By contrast, investors should also be aware of ongoing volatility in medical costs, such as the recent $130 million in unexpected Medicaid claims that...

Centene's outlook anticipates $195.6 billion in revenue and $2.1 billion in earnings by 2028. This is based on a 7.0% annual revenue growth rate, with earnings expected to remain flat at $2.1 billion, indicating no change from current levels.

Uncover how Centene's forecasts yield a $39.41 fair value, in line with its current price.

Exploring Other Perspectives

Sixteen fair value estimates from the Simply Wall St Community range from US$31.58 to US$191.76 per share. While many expect ongoing commercial segment growth supported by ACA subsidy extensions, your own outlook could shift as medical cost unpredictability remains a significant factor.

Explore 16 other fair value estimates on Centene - why the stock might be worth 20% less than the current price!

Build Your Own Centene Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Centene research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Centene research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Centene's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.